The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

Identificador:  imarina:9407097

Handle: https://hdl.handle.net/20.500.11797/imarina9407097

Autores:  Valdecantos, M Pilar; Ruiz, Laura; Folgueira, Cintia; Rada, Patricia; Gomez-Santos, Beatriz; Solas, Maite; Hitos, Ana B; Field, Joss; Francisco, Vera; Escalona-Garrido, Carmen; Zagmutt, Sebastian; Calderon-Dominguez, Maria; Mera, Paula; Garcia-Martinez, Irma; Maymo-Masip, Elsa; Grajales, Diana; Alen, Rosa; Mora, Alfonso; Sainz, Neira; Vides-Urrestarazu, Irene; Vilarrasa, Nuria; Arbones-Mainar, Jose M; Zaragoza, Carlos; Moreno-Aliaga, Maria J; Aspichueta, Patricia; Fernandez-Veledo, Sonia; Vendrell, Joan; Serra, Dolors; Herrero, Laura; Schreiber, Renate; Zechner, Rudolf; Sabio, Guadalupe; Hornigold, David; Rondinone, Cristina M; Jermutus, Lutz; Grimsby, Joseph; Valverde, angela M

Resumen:
Bariatric surgery is effective for the treatment and remission of obesity and type 2 diabetes, but pharmacological approaches which exert similar metabolic adaptations are needed to avoid post-surgical complications. Here we show how G49, an oxyntomodulin (OXM) analog and dual glucagon/glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas, and liver which is initiated by a rapid release of free fatty acids (FFAs) by white adipose tissue (WAT) in a GCGR-dependent manner. This interactome leads to elevations in adiponectin and fibroblast growth factor 21 (FGF21), causing WAT beiging, brown adipose tissue (BAT) activation, increased energy expenditure (EE) and weight loss. Elevation of OXM, under basal and postprandial conditions, and similar metabolic adaptations after G49 treatment were found in plasma from patients with obesity early after metabolic bariatric surgery. These results identify G49 as a potential pharmacological alternative sharing with bariatric surgery hormonal and metabolic pathways. G49, a dual glucagon/glucagon-like peptide-1 receptor agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas and liver, leading to brown fat activation with the final outcomes of increased energy expenditure and body weight loss.